United States

People: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

9 Dec 2016
Change (% chg)

$6.07 (+4.82%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hallal, David 

Mr. David L. Hallal is Chief Executive Officer, Director of Alexion Pharmaceuticals, Inc., since April 1, 2015. He has been with Alexion since June 2006 and has served as Chief Executive Officer (CEO) since April 2015. Mr. Hallal has also been a member of the Board of Directors since September 2014. Since joining Alexion, Mr. Hallal served as Chief Operating Office from September 2014 to April 2015 and in senior commercial positions, including Senior Vice President, US Commercial Operations from June 2006 until November 2008, Senior Vice President, Commercial Operations Americas from November 2008 to May 2010, Senior Vice President, Global Commercial Operations from May 2010 until October 2012 and then Executive Vice President and Chief Commercial Officer from October 2012 to September 2014. Prior to joining Alexion, Mr. Hallal served as Vice President, Sales at OSI Eyetech from April 2004 until June 2006, where he led the U.S. launch of a first-in-class anti-VEGF therapy for age-related macular degeneration. Prior to OSI Eyetech, from 1992 until 2004, Mr. Hallal held various sales and marketing leadership positions at Amgen and Biogen Idec, where he was involved in multiple product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal received a B.A. in Psychology from the University of New Hampshire.

Basic Compensation

Total Annual Compensation, USD 1,048,460
Restricted Stock Awards, USD 6,926,090
Long-Term Incentive Plans, USD --
All Other, USD 6,745,230
Fiscal Year Total, USD 14,719,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 30,000 5,088,460.00
Name Fiscal Year Total

Leonard Bell


David Hallal


Vikas Sinha


Clare Carmichael


John Moriarty


Saqib Islam

As Of  30 Dec 2015